London, United Kingdom (CU)_ The European Commission has approved a joint procurement agreement with GlaxoSmithKline (GSK) and Vir Biotechnology for the supply of up to 220,000 doses of sotrovimab to be used in the treatment of Covid-19. Sotrovimab is an experimental single-dose SARS-CoV-2 monoclonal antibody manufactured in collaboration with Vir Biotechnology for the treatment of Covid-19 in patients aged 12 and up who do not require oxygen but have the risk of developing severe disease.
Following the local emergency approval or EU-level approval, participating European Union (EU) member states can…
